What changed: Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)
Every dated change on the records linked to Localised adrenocortical carcinoma (ENSAT stage I to III, resectable), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2023 · 1
2018 · 6
- 2018GuidelineLocalised adrenocortical carcinoma (ENSAT stage I to III, resectable)Guideline ESE/ENSAT guideline on adrenocortical carcinoma 2018: After complete resection, low risk
Observation with imaging every three months (ADIUVO showed no benefit from mitotane).
- 2018GuidelineLocalised adrenocortical carcinoma (ENSAT stage I to III, resectable)Guideline ESE/ENSAT guideline on adrenocortical carcinoma 2018: After resection, high risk
Adjuvant mitotane titrated to 14 to 20 mg/L for at least two years with glucocorticoid replacement; tumour-bed radiotherapy after incomplete resection; platinum-based chemotherapy considered for very high-risk tumours (ADIUVO-2).
- 2018GuidelineLocalised adrenocortical carcinoma (ENSAT stage I to III, resectable)Guideline ESE/ENSAT guideline on adrenocortical carcinoma 2018: Diagnosis and staging
Hormone work-up, contrast CT or MRI of the adrenal, chest CT and FDG-PET; no biopsy of a resectable adrenal mass; germline testing.
- 2018GuidelineLocalised adrenocortical carcinoma (ENSAT stage I to III, resectable)Guideline ESE/ENSAT guideline on adrenocortical carcinoma 2018: Local recurrence
Repeat resection when feasible after a disease-free interval of a year or more, with mitotane; ablation or radiotherapy for small unresectable recurrences.
- 2018GuidelineLocalised adrenocortical carcinoma (ENSAT stage I to III, resectable)Guideline ESE/ENSAT guideline on adrenocortical carcinoma 2018: Resectable disease
Open adrenalectomy with en bloc resection of adherent structures and locoregional lymphadenectomy by an experienced surgeon; laparoscopic surgery only for small tumours; perioperative hydrocortisone for cortisol-secreting tumours.
- 2018MilestoneMitotaneESE/ENSAT guideline sets Ki-67 and resection status as the basis for adjuvant mitotane
A milestone in how this cancer is treated.